Dr. Lipkin is a physician-scientist who has published in Cell, Cell Stem Cell, Nature Biotechnology, Nature Genetics, Science, Genes and Development, Proceedings of the National Academy of Sciences and Journal of Clinical Investigation, among others.

He is Vice Chair for Research, Weill-Cornell Department of Medicine. He is a member of the FDA Molecular and Clinical Genetics Panel, which reviews and votes on approval of new genetic tests in the US. He is Director of the Weill Cornell Medical College Adult and Cancer Genetics Clinic, where he practices as a Clinical Geneticist and supervises Genetic Counselors, and Director of the Program in Mendelian Genetics.  He directs a research laboratory that uses massively parallel sequencing, computational biology, mouse models, cell culture and genomics to understand the contribution of genetics to, and mechanisms of, hereditary cancer genetic syndromes. He discovered and mechanistically characterized MLH3, a DNA mismatch repair gene colorectal polyposis and cancer predisposition gene. He has also identified or co-identified 6 B cell malignancy predisposition genes. His lab made important contributions to our understanding of cancer initiating cells and was also the first to model human cancer cells in immune competent mice. He currently leads an NCI multi-institutional Center for Cancer Immunoprevention.  He is currently working on developing and validating precision prevention and precision therapies for patients with DNA repair deficient cancers.